CareDx, Inc (NASDAQ:CDNA) Shares Sold by Hanseatic Management Services Inc.

Hanseatic Management Services Inc. lowered its position in shares of CareDx, Inc (NASDAQ:CDNA) by 30.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,277 shares of the company’s stock after selling 7,721 shares during the period. Hanseatic Management Services Inc.’s holdings in CareDx were worth $370,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Principal Financial Group Inc. purchased a new position in shares of CareDx during the third quarter worth about $557,000. Lord Abbett & CO. LLC acquired a new position in shares of CareDx in the third quarter valued at approximately $10,873,000. Franklin Resources Inc. increased its stake in CareDx by 34.4% in the 3rd quarter. Franklin Resources Inc. now owns 59,474 shares of the company’s stock valued at $1,862,000 after buying an additional 15,238 shares during the period. Virtue Capital Management LLC purchased a new position in CareDx during the third quarter worth about $755,000. Finally, Geode Capital Management LLC raised its stake in shares of CareDx by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,227,724 shares of the company’s stock worth $38,343,000 after buying an additional 32,141 shares in the last quarter.

Insider Activity

In other news, Director Peter Maag sold 5,000 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the director now directly owns 330,024 shares of the company’s stock, valued at approximately $8,250,600. The trade was a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.90% of the company’s stock.

CareDx Price Performance

CareDx stock opened at $21.44 on Friday. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -7.94 and a beta of 1.86. CareDx, Inc has a 12 month low of $7.42 and a 12 month high of $34.84. The stock’s 50-day moving average is $22.90 and its 200-day moving average is $24.52.

CareDx (NASDAQ:CDNA) last posted its earnings results on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.11. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The business had revenue of $82.88 million for the quarter, compared to analyst estimates of $80.04 million. During the same quarter in the previous year, the business posted ($0.43) EPS. The business’s quarterly revenue was up 23.4% on a year-over-year basis. Research analysts anticipate that CareDx, Inc will post -0.7 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. The Goldman Sachs Group increased their price target on shares of CareDx from $26.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Wells Fargo & Company upgraded CareDx from an “underweight” rating to an “equal weight” rating and dropped their target price for the company from $28.00 to $24.00 in a research note on Wednesday. HC Wainwright restated a “neutral” rating and issued a $26.00 price target on shares of CareDx in a report on Tuesday, January 14th. StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a report on Thursday, October 17th. Finally, BTIG Research decreased their target price on shares of CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, November 5th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, CareDx presently has an average rating of “Moderate Buy” and a consensus price target of $28.33.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.